8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
Apr 15, 2026·SEC
Integra LifeSciences Holdings Corporation(IART)Earnings, Financials & Key Ratios
IART•NASDAQ
$14.00
$1.09B mkt cap·Price updated May 6, 2026
AboutIntegra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.Show more
- Revenue$1.64B+1.5%
- EBITDA$219M+29.9%
- Net Income-$516M-7337.7%
- EPS (Diluted)-6.73-7361.2%
- Gross Margin51.69%-5.6%
- EBITDA Margin13.41%+27.9%
- Operating Margin4.18%+136.8%
- Net Margin-31.58%-7224.7%
- ROE-39.9%-8901.0%
- ROIC1.67%+146.4%
- Debt/Equity1.95+51.7%
- Interest Coverage-5.53-845.9%
IART Key Insights
Integra LifeSciences Holdings Corporation (IART) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
IART Price & Volume
Integra LifeSciences Holdings Corporation (IART) stock price & volume — 10-year historical chart
Loading chart...
IART Growth Metrics
Integra LifeSciences Holdings Corporation (IART) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years6.36%
5 Years3.57%
3 Years1.63%
TTM1.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1612.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1605.95%
Return on Capital
10 Years3.99%
5 Years3.79%
3 Years2.07%
Last Year2.18%
IART Recent Earnings
Integra LifeSciences Holdings Corporation (IART) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026EPS
$0.54
Est $0.41
+31.7%
Revenue
$392M
Est $382M
+2.6%
Q1 2026
Feb 26, 2026EPS
$0.83
Est $0.79
+5.1%
Revenue
$435M
Est $430M
+1.2%
Q4 2025
Oct 30, 2025EPS
$0.54
Est $0.43
+25.6%
Revenue
$402M
Est $430M
-6.4%
Q3 2025
Jul 31, 2025EPS
$0.45
Est $0.43
+4.7%
Revenue
$416M
Est $414M
+0.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.54vs $0.41+31.7% | $392Mvs $382M+2.6% |
| Q1 2026 | Feb 26, 2026 | $0.83vs $0.79+5.1% | $435Mvs $430M+1.2% |
| Q4 2025 | Oct 30, 2025 | $0.54vs $0.43+25.6% | $402Mvs $430M-6.4% |
| Q3 2025 | Jul 31, 2025 | $0.45vs $0.43+4.7% | $416Mvs $414M+0.3% |
Based on last 12 quarters of dataView full earnings history →
IART Peer Comparison
Integra LifeSciences Holdings Corporation (IART) competitors in Aesthetics, dermatology, and wound care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 10.37% | 5.42% | 0.52 |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ATRC | 1.42B | 28.01 | -116.71 | 14.88% | -2.14% | -2.43% | 3.4% | 0.18 |
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.23% | 0.16 |
 MMSI | 3.68B | 61.63 | 28.93 | 11.66% | 9.03% | 8.95% | 5.87% | 0.57 |
 LMAT | 2.51B | 110.22 | 43.74 | 13.53% | 23.13% | 15.58% | 2.97% | 0.47 |
 GMED | 12.07B | 89.22 | 22.76 | 16.65% | 18.3% | 12.4% | 4.88% | 0.03 |
 AORT | 1.68B | 34.70 | 165.24 | 13.59% | 2.21% | 2.44% | 0.65 |
Compare IART vs Peers
Integra LifeSciences Holdings Corporation (IART) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IART Income Statement
Integra LifeSciences Holdings Corporation (IART) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.19B | 1.47B | 1.52B | 1.37B | 1.54B | 1.56B | 1.54B | 1.61B | 1.64B | 1.64B |
| Revenue Growth % | 19.77% | 23.92% | 3.06% | -9.6% | 12.43% | 0.99% | -1.03% | 4.47% | 1.53% | 1.24% |
| Cost of Goods Sold | 435.51M | 571.5M | 564.68M | 520.83M | 597.81M | 587.36M | 656.84M | 728.47M | 790.01M | 601.79M |
| COGS % of Revenue | 36.65% | 38.81% | 37.21% | 37.97% | 38.76% | 37.71% | 42.61% | 45.23% | 48.31% | - |
| Gross Profit | 752.73M▲ 0% | 900.95M▲ 19.7% | 952.88M▲ 5.8% | 851.03M▼ 10.7% | 944.64M▲ 11.0% | 970.31M▲ 2.7% | 884.74M▼ 8.8% | 882.06M▼ 0.3% | 845.23M▼ 4.2% | 650.8M▲ 0% |
| Gross Margin % | 63.35% | 61.19% | 62.79% | 62.03% | 61.24% | 62.29% | 57.39% | 54.77% | 51.69% | 39.57% |
| Gross Profit Growth % | 17.07% | 19.69% | 5.76% | -10.69% | 11% | 2.72% | -8.82% | -0.3% | -4.18% | - |
| Operating Expenses | 707.92M | 789.95M | 859.12M | 699.66M | 747.41M | 731.39M | 773.21M | 853.65M | 776.92M | 768.72M |
| OpEx % of Revenue | 59.58% | 53.65% | 56.61% | 51% | 48.46% | 46.95% | 50.16% | 53% | 47.51% | - |
| Selling, General & Admin | 624.1M | 690.75M | 687.6M | 594.53M | 637.45M | 616.32M | 656.64M | 716.98M | 699.7M | 696.44M |
| SG&A % of Revenue | 52.52% | 46.91% | 45.31% | 43.34% | 41.33% | 39.57% | 42.6% | 44.52% | 42.79% | - |
| Research & Development | 63.45M | 78.04M | 79.57M | 77.38M | 93.05M | 101.19M | 104.19M | 115.38M | 98.97M | 97.75M |
| R&D % of Revenue | 5.34% | 5.3% | 5.24% | 5.64% | 6.03% | 6.5% | 6.76% | 7.16% | 6.05% | - |
| Other Operating Expenses | 1.34M | 8.29M | 91.94M | 27.76M | 16.91M | 13.88M | 12.38M | 21.29M | -21.75M | -1000K |
| Operating Income | 44.8M▲ 0% | 111M▲ 147.7% | 93.76M▼ 15.5% | 151.37M▲ 61.4% | 197.23M▲ 30.3% | 238.92M▲ 21.1% | 111.53M▼ 53.3% | 28.41M▼ 74.5% | 68.32M▲ 140.5% | 95.28M▲ 0% |
| Operating Margin % | 3.77% | 7.54% | 6.18% | 11.03% | 12.79% | 15.34% | 7.23% | 1.76% | 4.18% | 5.79% |
| Operating Income Growth % | -61.15% | 147.74% | -15.53% | 61.44% | 30.3% | 21.14% | -53.32% | -74.53% | 140.46% | - |
| EBITDA | 133.7M | 226.7M | 203.22M | 270.36M | 320.9M | 360.04M | 235.04M | 168.91M | 219.37M | 209.14M |
| EBITDA Margin % | 11.25% | 15.4% | 13.39% | 19.71% | 20.8% | 23.11% | 15.25% | 10.49% | 13.41% | 12.72% |
| EBITDA Growth % | -28.88% | 69.55% | -10.36% | 33.03% | 18.7% | 12.2% | -34.72% | -28.13% | 29.87% | 33.75% |
| D&A (Non-Cash Add-back) | 88.9M | 115.7M | 109.46M | 118.99M | 123.67M | 121.11M | 123.51M | 140.5M | 151.05M | 113.86M |
| EBIT | 46.33M | 125.34M | 114.06M | 148.95M | 242.66M | 263.49M | 132.45M | 52.4M | -477.25M | -466.03M |
| Net Interest Income | -34.76M | -61.88M | -43.18M | -62.28M | -43.66M | -37.68M | -34.17M | -50.59M | -67.78M | -53.39M |
| Interest Income | 255K | 2.8M | 10.78M | 9.3M | 6.74M | 11.92M | 17.2M | 20.04M | 18.47M | 18.16M |
| Interest Expense | 35.02M | 64.68M | 53.96M | 71.58M | 50.4M | 49.59M | 51.38M | 70.63M | 86.25M | 44.98M |
| Other Income/Expense | -33.42M | -53.59M | -33.66M | -57.85M | 17.45M | -25.03M | -30.46M | -46.65M | -631.82M | -631.16M |
| Pretax Income | 11.38M▲ 0% | 57.4M▲ 404.2% | 60.1M▲ 4.7% | 93.52M▲ 55.6% | 214.68M▲ 129.6% | 213.89M▼ 0.4% | 81.07M▼ 62.1% | -18.24M▼ 122.5% | -563.5M▼ 2989.9% | -535.88M▲ 0% |
| Pretax Margin % | 0.96% | 3.9% | 3.96% | 6.82% | 13.92% | 13.73% | 5.26% | -1.13% | -34.46% | -32.59% |
| Income Tax | -53.36M | -3.4M | 9.9M | -40.37M | 45.6M | 33.34M | 13.33M | -11.29M | -47.03M | -40.08M |
| Effective Tax Rate % | -468.67% | -5.92% | 16.48% | -43.17% | 21.24% | 15.59% | 16.44% | 61.92% | 8.35% | 7.48% |
| Net Income | 64.74M▲ 0% | 60.8M▼ 6.1% | 50.2M▼ 17.4% | 133.89M▲ 166.7% | 169.07M▲ 26.3% | 180.55M▲ 6.8% | 67.74M▼ 62.5% | -6.94M▼ 110.3% | -516.47M▼ 7337.7% | -495.8M▲ 0% |
| Net Margin % | 5.45% | 4.13% | 3.31% | 9.76% | 10.96% | 11.59% | 4.39% | -0.43% | -31.58% | -30.15% |
| Net Income Growth % | -13.17% | -6.09% | -17.43% | 166.71% | 26.28% | 6.79% | -62.48% | -110.25% | -7337.7% | -1612.31% |
| Net Income (Continuing) | 64.74M | 60.8M | 50.2M | 133.89M | 169.07M | 180.55M | 67.74M | -6.94M | -516.47M | -495.8M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.82▲ 0% | 0.72▼ 12.2% | 0.58▼ 19.4% | 1.57▲ 170.7% | 1.98▲ 26.1% | 2.16▲ 9.1% | 0.84▼ 61.1% | -0.09▼ 110.7% | -6.73▼ 7361.2% | -6.44▲ 0% |
| EPS Growth % | -12.77% | -12.2% | -19.44% | 170.69% | 26.11% | 9.09% | -61.11% | -110.74% | -7361.2% | -1605.95% |
| EPS (Basic) | 0.83 | 0.73 | 0.59 | 1.58 | 2.00 | 2.18 | 0.87 | -0.09 | -6.73 | - |
| Diluted Shares Outstanding | 79.12M | 84.45M | 86.49M | 85.23M | 85.48M | 83.52M | 80.34M | 77.01M | 76.75M | 76.95M |
| Basic Shares Outstanding | 78.39M | 82.86M | 85.64M | 84.65M | 84.7M | 83M | 78.17M | 77.01M | 76.75M | 76.95M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
IART Balance Sheet
Integra LifeSciences Holdings Corporation (IART) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 822.15M | 775.08M | 858.17M | 1.24B | 1.15B | 1.16B | 1.06B | 1.08B | 1.16B | 1.02B |
| Cash & Short-Term Investments | 174.94M | 138.84M | 198.91M | 470.17M | 513.45M | 456.66M | 309.1M | 273.57M | 263.74M | 265.5M |
| Cash Only | 174.94M | 138.84M | 198.91M | 470.17M | 513.45M | 456.66M | 276.4M | 246.38M | 235.05M | 236.81M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 32.69M | 27.19M | 28.69M | 28.69M |
| Accounts Receivable | 251.8M | 265.74M | 275.3M | 225.53M | 231.83M | 263.46M | 259.33M | 272.37M | 278.85M | 264.41M |
| Days Sales Outstanding | 77.35 | 65.87 | 66.21 | 60.01 | 54.86 | 61.74 | 61.4 | 61.73 | 62.24 | 60.48 |
| Inventory | 296.33M | 280.35M | 316.05M | 310.12M | 317.39M | 324.58M | 389.61M | 429.09M | 492.74M | 495.04M |
| Days Inventory Outstanding | 248.35 | 179.05 | 204.29 | 217.33 | 193.78 | 201.71 | 216.5 | 215 | 227.65 | 294.47 |
| Other Current Assets | 99.08M | 0 | 0 | 162.1M | 0 | 31.03M | 32.64M | 29.65M | 124.22M | 0 |
| Total Non-Current Assets | 2.39B | 2.33B | 2.45B | 2.38B | 2.63B | 2.73B | 2.72B | 2.96B | 2.44B | 2.41B |
| Property, Plant & Equipment | 269.25M | 300.11M | 431.93M | 371.16M | 396.25M | 459.59M | 496.38M | 549.76M | 584.9M | 0 |
| Fixed Asset Turnover | 4.41x | 4.91x | 3.51x | 3.70x | 3.89x | 3.39x | 3.11x | 2.93x | 2.80x | 5.74x |
| Goodwill | 937.9M | 926.48M | 954.28M | 932.37M | 1.01B | 1.04B | 1.06B | 1.1B | 615.16M | 613.25M |
| Intangible Assets | 1.16B | 1.08B | 1.03B | 989.44M | 1.15B | 1.13B | 1.07B | 1.21B | 1.13B | 1.11B |
| Long-Term Investments | 2.49M | 5.35M | 3.46M | 474.83M | 6.48M | 567.34M | 30.71M | 38.3M | 12.78M | 18.5M |
| Other Non-Current Assets | 13.59M | 14.57M | 11.18M | -463.56M | 9.96M | -510.15M | 27.48M | 28.21M | 25.1M | 1.45B |
| Total Assets | 3.21B▲ 0% | 3.11B▼ 3.2% | 3.3B▲ 6.3% | 3.62B▲ 9.4% | 3.78B▲ 4.6% | 3.89B▲ 2.8% | 3.78B▼ 2.8% | 4.04B▲ 6.8% | 3.6B▼ 10.8% | 3.58B▲ 0% |
| Asset Turnover | 0.37x | 0.47x | 0.46x | 0.38x | 0.41x | 0.40x | 0.41x | 0.40x | 0.45x | 0.45x |
| Asset Growth % | 77.62% | -3.22% | 6.29% | 9.44% | 4.63% | 2.84% | -2.77% | 6.75% | -10.78% | -42.8% |
| Total Current Liabilities | 348.91M | 262.55M | 331.31M | 401.01M | 340.02M | 320.91M | 306.98M | 922.13M | 455.98M | 346.85M |
| Accounts Payable | 93.97M | 76.05M | 113.09M | 54.61M | 61.84M | 102.1M | 92.33M | 82.5M | 95.73M | 0 |
| Days Payables Outstanding | 78.75 | 48.57 | 73.1 | 38.27 | 37.76 | 63.45 | 51.3 | 41.34 | 44.23 | 42.59 |
| Short-Term Debt | 60M | 22.5M | 57.25M | 146.25M | 59.77M | 52.75M | 14.53M | 607.08M | 126.55M | 52.68M |
| Deferred Revenue (Current) | 11.05M | 3.76M | 4.77M | 5.28M | 5.29M | 7.25M | 8.54M | 10.48M | 0 | 22.43M |
| Other Current Liabilities | 110.5M | 75.69M | 67.13M | 105.94M | 105.68M | 65.41M | 100.84M | 37.79M | 216.03M | 294.16M |
| Current Ratio | 2.36x | 2.95x | 2.59x | 3.09x | 3.39x | 3.62x | 3.45x | 1.17x | 2.54x | 2.54x |
| Quick Ratio | 1.51x | 1.88x | 1.64x | 2.31x | 2.46x | 2.61x | 2.18x | 0.71x | 1.46x | 1.46x |
| Cash Conversion Cycle | 246.95 | 196.35 | 197.41 | 239.07 | 210.89 | 199.99 | 226.6 | 235.39 | 245.67 | 312.36 |
| Total Non-Current Liabilities | 1.9B | 1.47B | 1.56B | 1.7B | 1.76B | 1.76B | 1.89B | 1.57B | 2.1B | 2.19B |
| Long-Term Debt | 1.78B | 1.33B | 1.3B | 1.41B | 1.5B | 1.41B | 1.49B | 1.2B | 1.73B | 160.12M |
| Capital Lease Obligations | 0 | 0 | 97.5M | 88.12M | 90.33M | 157.42M | 166.85M | 166.93M | 163.06M | 483.26M |
| Deferred Tax Liabilities | 65.13M | 57.78M | 36.55M | 16.19M | 45.79M | 63.34M | 35.32M | 60.83M | 5.66M | 130.16M |
| Other Non-Current Liabilities | 53.77M | 80.05M | 125.07M | 186.73M | 120.26M | 138.5M | 192.24M | 137.04M | 204.28M | 2.7B |
| Total Liabilities | 2.25B | 1.73B | 1.89B | 2.1B | 2.1B | 2.09B | 2.19B | 2.49B | 2.56B | 2.54B |
| Total Debt | 1.84B | 1.35B | 1.46B | 1.66B | 1.67B | 1.63B | 1.68B | 1.98B | 2.03B | 212.8M |
| Net Debt | 1.67B | 1.22B | 1.26B | 1.19B | 1.15B | 1.17B | 1.41B | 1.74B | 1.8B | -24.01M |
| Debt / Equity | 1.91x | 0.98x | 1.03x | 1.09x | 0.99x | 0.90x | 1.06x | 1.28x | 1.95x | 1.95x |
| Debt / EBITDA | 13.77x | 5.97x | 7.17x | 6.12x | 5.19x | 4.53x | 7.15x | 11.75x | 9.27x | 1.02x |
| Net Debt / EBITDA | 12.46x | 5.36x | 6.19x | 4.38x | 3.59x | 3.26x | 5.98x | 10.29x | 8.20x | 8.20x |
| Interest Coverage | 1.32x | 1.94x | 2.11x | 2.08x | 4.82x | 5.31x | 2.58x | 0.74x | -5.53x | -10.36x |
| Total Equity | 962.31M▲ 0% | 1.38B▲ 43.0% | 1.42B▲ 3.0% | 1.51B▲ 6.9% | 1.68B▲ 11.2% | 1.8B▲ 7.1% | 1.59B▼ 12.0% | 1.55B▼ 2.7% | 1.04B▼ 32.5% | 1.04B▲ 0% |
| Equity Growth % | 14.61% | 42.97% | 2.98% | 6.93% | 11.22% | 7.1% | -12% | -2.68% | -32.47% | -128.19% |
| Book Value per Share | 12.16 | 16.29 | 16.38 | 17.77 | 19.71 | 21.61 | 19.77 | 20.07 | 13.60 | 13.55 |
| Total Shareholders' Equity | 962.31M | 1.38B | 1.42B | 1.51B | 1.68B | 1.8B | 1.59B | 1.55B | 1.04B | 1.04B |
| Common Stock | 813K | 880K | 887K | 893K | 896K | 905K | 909K | 916K | 923K | 922K |
| Retained Earnings | 285.19M | 348.37M | 398.57M | 532.26M | 698.57M | 879.12M | 946.86M | 939.91M | 423.44M | 418.82M |
| Treasury Stock | -121.64M | -120.61M | -119.94M | -235.14M | -234.45M | -362.86M | -647.26M | -691.41M | -689.21M | 0 |
| Accumulated OCI | -23.81M | -45.44M | -76.4M | -74.06M | -45.16M | 10.27M | -15.11M | -27.57M | -30.08M | -30.94M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IART Cash Flow Statement
Integra LifeSciences Holdings Corporation (IART) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 114.54M | 199.68M | 231.43M | 203.83M | 312.43M | 264.47M | 139.96M | 129.38M | 50.38M | 50.38M |
| Operating CF Margin % | 9.64% | 13.56% | 15.25% | 14.86% | 20.26% | 16.98% | 9.08% | 8.03% | 3.08% | - |
| Operating CF Growth % | -1.6% | 74.33% | 15.9% | -11.93% | 53.28% | -15.35% | -47.08% | -7.55% | -61.06% | 114.37% |
| Net Income | 64.74M | 60.8M | 50.2M | 133.89M | 169.07M | 180.55M | 67.74M | -6.94M | -516.47M | -495.8M |
| Depreciation & Amortization | 88.94M | 110.73M | 109.46M | 116.03M | 119.84M | 118.3M | 123.51M | 140.89M | 0 | 76.21M |
| Stock-Based Compensation | 21.55M | 20.78M | 21.25M | 19.59M | 36.21M | 27.73M | 20.14M | 24.38M | 0 | 10.88M |
| Deferred Taxes | -67.3M | -8.18M | -19.05M | -64.14M | -2.75M | -4.58M | -11.88M | -20.73M | 0 | -55.32M |
| Other Non-Cash Items | 7.93M | 13.81M | 84.07M | 39.77M | -28.1M | -18.1M | 22.02M | 22.79M | 600.59M | 542.85M |
| Working Capital Changes | -1.32M | 1.75M | -14.51M | -41.31M | 18.16M | -39.42M | -81.57M | -31.01M | -33.74M | -9.08M |
| Change in Receivables | -89.7M | -17.02M | -9.43M | 52.1M | 7.26M | -33.91M | 4.59M | 7.4M | -485K | -21.94M |
| Change in Inventory | 99K | 8.3M | -43.31M | -48.35M | 5.37M | -29.12M | -59.77M | -28.15M | -46.76M | -33.06M |
| Change in Payables | 95.32M | 3.59M | 14.67M | -57.51M | 32.87M | 17.34M | -20.23M | -2.67M | 26.72M | 44.72M |
| Cash from Investing | -1.22B | -49.7M | -162.67M | -68.07M | -161.44M | -58.58M | -94.18M | -390.81M | -108.06M | -86.99M |
| Capital Expenditures | -43.5M | -77.74M | -69.54M | -63.89M | -48.02M | -47.09M | -66.86M | -104.42M | 0 | -99.22M |
| CapEx % of Revenue | 3.66% | 5.28% | 4.58% | 4.66% | 3.11% | 3.02% | 4.34% | 6.48% | 4.98% | - |
| Acquisitions | -1.2B | 26.7M | -30.51M | 3.66M | -113.44M | -27.55M | 0 | -277.81M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 483K | 1.33M | -64.21M | 3.66M | -55K | 16.05M | 0 | -14.08M | -108.06M | 22.66M |
| Cash from Financing | 1.17B | -180.87M | -8.77M | 121.63M | -98.23M | -251.95M | -229.93M | 237.86M | 28.34M | 1.25M |
| Debt Issued (Net) | 1.19B | -488.8M | -9.2M | 305.5M | -100M | -107.8M | 54.5M | 299.37M | 46.75M | 7.67M |
| Equity Issued (Net) | -7.12M | 349.59M | 0 | -105.08M | 0 | -119.53M | -275M | -52.47M | 736K | -221K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -7.12M | 0 | 0 | -100M | 0 | -125M | -275M | -52.47M | -221K | -442K |
| Other Financing | -13.93M | -41.66M | 434K | -78.8M | 1.77M | -24.62M | -9.43M | -9.04M | -19.15M | -6.19M |
| Net Change in Cash | 72.88M▲ 0% | -36.1M▼ 149.5% | 60.07M▲ 266.4% | 271.25M▲ 351.5% | 43.28M▼ 84.0% | -56.79M▼ 231.2% | -180.26M▼ 217.4% | -30.03M▲ 83.3% | -11.33M▲ 62.3% | -2.29M▲ 0% |
| Free Cash Flow | 71.04M▲ 0% | 121.94M▲ 71.7% | 96.9M▼ 20.5% | 139.94M▲ 44.4% | 264.35M▲ 88.9% | 217.38M▼ 17.8% | 73.09M▼ 66.4% | 24.96M▼ 65.8% | -31.05M▼ 224.4% | -12.92M▲ 0% |
| FCF Margin % | 5.98% | 8.28% | 6.39% | 10.2% | 17.14% | 13.96% | 4.74% | 1.55% | -1.9% | -0.79% |
| FCF Growth % | 2.84% | 71.65% | -20.54% | 44.42% | 88.9% | -17.77% | -66.38% | -65.84% | -224.39% | 49.23% |
| FCF per Share | 0.90 | 1.44 | 1.12 | 1.64 | 3.09 | 2.60 | 0.91 | 0.32 | -0.40 | -0.40 |
| FCF Conversion (FCF/Net Income) | 1.77x | 3.28x | 4.61x | 1.52x | 1.85x | 1.46x | 2.07x | -18.63x | -0.10x | 0.03x |
| Interest Paid | 32.3K | 58.3K | 48.9K | 47.3K | 43.2M | 42.2M | 44.3M | 64.4M | 0 | 0 |
| Taxes Paid | 14.6K | 10.4K | 16.2K | 29.8K | 49.5M | 35.9M | 23.6M | 22.7M | 0 | 0 |
IART Key Ratios
Integra LifeSciences Holdings Corporation (IART) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 7.19% | 5.2% | 3.6% | 9.13% | 10.57% | 10.35% | 3.99% | -0.44% | -39.9% | -47.65% |
| Return on Invested Capital (ROIC) | 1.67% | 3.19% | 2.67% | 4.22% | 5.34% | 6.16% | 2.8% | 0.68% | 1.67% | 1.67% |
| Gross Margin | 63.35% | 61.19% | 62.79% | 62.03% | 61.24% | 62.29% | 57.39% | 54.77% | 51.69% | 39.57% |
| Net Margin | 5.45% | 4.13% | 3.31% | 9.76% | 10.96% | 11.59% | 4.39% | -0.43% | -31.58% | -30.15% |
| Debt / Equity | 1.91x | 0.98x | 1.03x | 1.09x | 0.99x | 0.90x | 1.06x | 1.28x | 1.95x | 1.95x |
| Interest Coverage | 1.32x | 1.94x | 2.11x | 2.08x | 4.82x | 5.31x | 2.58x | 0.74x | -5.53x | -10.36x |
| FCF Conversion | 1.77x | 3.28x | 4.61x | 1.52x | 1.85x | 1.46x | 2.07x | -18.63x | -0.10x | 0.03x |
| Revenue Growth | 19.77% | 23.92% | 3.06% | -9.6% | 12.43% | 0.99% | -1.03% | 4.47% | 1.53% | 1.24% |
IART SEC Filings & Documents
Integra LifeSciences Holdings Corporation (IART) SEC filings — annual & quarterly reports (10-K, 10-Q)
IART Frequently Asked Questions
Integra LifeSciences Holdings Corporation (IART) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Integra LifeSciences Holdings Corporation (IART) reported $1.64B in revenue for fiscal year 2025. This represents a 12454% increase from $13.1M in 1996.
Integra LifeSciences Holdings Corporation (IART) grew revenue by 1.5% over the past year. Growth has been modest.
Integra LifeSciences Holdings Corporation (IART) reported a net loss of $495.8M for fiscal year 2025.
Dividend & Returns
Integra LifeSciences Holdings Corporation (IART) has a return on equity (ROE) of -39.9%. Negative ROE indicates the company is unprofitable.
Integra LifeSciences Holdings Corporation (IART) had negative free cash flow of $12.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More IART
Integra LifeSciences Holdings Corporation (IART) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates